Experts discuss how the integration of continuous glucose monitoring (CGM) data into electronic health record (EHR) systems enhances clinical decision-making and care coordination, how primary care ...

Medical device companies presented new data this week at the Advanced Technologies & Treatments for Diabetes conference.

DexCom receives a warning letter from the FDA citing several issues with its popular G6 & G7 sensor manufacturing. The ...

Dexcom made a significant design change to a component used in its sensors and did not adequately validate the change, ...

SiBionics announced today that it unveiled its GS3 continuous glucose monitor (CGM), which now has CE mark approval.

A real-world analysis showed a link between continuous glucose monitor (CGM) distribution channel and outcomes for patients with diabetes.

CGMs are transforming health tracking for non-diabetics, providing insights into glucose levels and influencing dietary choices and athletic performance.

DexCom, Inc. DXCM recently unveiled new data for its upcoming G7 15-day continuous glucose monitoring (CGM) sensor at the Advanced Technologies & Treatments for Diabetes (ATTD) conference 2025. With ...

The U.S. FDA’s March 4, 2025, warning letter to Dexcom Inc. is a well-detailed but heavily redacted document explaining the agency’s misgivings about procedures such as monitoring of acetaminophen ...

The agency cited quality issues at facilities testing Dexcom’s G6 and G7 monitors, including inadequate validation and risk ...

Nanowear announced that it entered into a partnership with Dexcom to ingest glucose data from its latest continuous glucose ...

Beta Bionics recently brought its iLet bionic pancreas to market in 2023 and completed an IPO to become a publicly-traded ...